Top

Current Breast Cancer Reports

Published in:

01-06-2020 | Breast Cancer | Breast Cancer Genetics (BK Arun, Section Editor)

Panel Testing for Hereditary Breast Cancer: More or Less?

Authors: Kara K. Landry, Marie E. Wood

Published in: Current Breast Cancer Reports | Issue 2/2020

Abstract

Purpose of Review

Panel testing is increasingly being offered to patients. Currently, women may be offered a panel of up to 80 genes. Oncologists are tasked with understanding the indications for this testing as well as the potential implications. In this review, we outline which patients should undergo genetic testing for hereditary breast cancer, when this testing should be performed, and which genes should be tested for.

Recent Findings

Our understanding of hereditary breast cancer has drastically changed with the advent of next generation sequencing (NGS), and many additional genes have been associated with increased breast cancer risk. Some have advocated for genetic testing of all women with breast cancer.

Summary

Routine genetic testing for all women with breast cancer is not warranted. Women with a phenotype associated with hereditary breast cancer, with a family history of cancer, or for whom a positive genetic test would change management should be offered genetic testing.

Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet. 2010;11(1):31–46.PubMedCrossRef

Supreme Court of the United States syllabus. Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al. certiorari to the United States Court of Appeals for the Federal Circuit. Rev Derecho Genoma Hum. 2013 (38):217–9.

Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Garber JE Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–8.PubMedPubMedCentralCrossRef

• Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305–15 An important paper which identified important gaps and disparities in testing for hereditary breast and ovarian cancer. PubMedPubMedCentralCrossRef

• Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of Hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453–60 An important paper which demonstrates that guidelines do identifiy women with BRCA mutations, but expanding testing guidelines may reach more mutation carriers. PubMedCrossRef

Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 2017;3(9):1190–6.PubMedPubMedCentralCrossRef

Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes-providing evidence of cancer predisposition genes. Gynecol Oncol. 2019;153(2):452–62.PubMedCrossRef

• Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–30 An important paper which demonstrates featues most consistent with BRCA related cancers. PubMedCrossRef

O'Leary E, Iacoboni D, Holle J, Michalski ST, Esplin ED, Yang S. Ouyang K Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol. 2017;24(10):3060–6.PubMedPubMedCentralCrossRef

10.

•• Force USPST, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652–65 Very important and up to date guidelines for genetic testing. CrossRef

11.

Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American Society of Clinical Oncology Expert statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32(8):833–40.PubMedPubMedCentralCrossRef

12.

Lancaster JM, Powell CB, Chen LM, Richardson DL, Committee SGOCP. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3–7.PubMedCrossRef

13.

Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw. 2017;15(1):9–20.CrossRef

14.

Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. Lindor NM American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660–7.PubMedCrossRef

15.

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group ACoMG, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87.PubMedCrossRef

16.

Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H. Multigene panel testing provides a new perspective on Lynch syndrome. J Clin Oncol. 2017;35(22):2568–75.PubMedPubMedCentralCrossRef

17.

Genetic/Familial High-Risk Assessment (2019): Breast O, and Pancreatic. In: NCCN Clin, Pract. Guidel. Oncol. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Accessed 12.6.2019.

18.

Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, et al. Daniels M Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in patients with breast cancer. J Natl Compr Cancer Netw. 2017;15(6):797–803.CrossRef

19.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Levy-Lahad E Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205–10.PubMedPubMedCentralCrossRef

20.

Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25(43):5906–11.PubMedCrossRef

21.

Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831–6.PubMedCrossRef

22.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26(4):542–8.PubMedCrossRef

23.

Consortium CBCC-C. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004;74(6):1175–82.CrossRef

24.

Jerzak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol. 2018;25(2):e176–e80.PubMedPubMedCentralCrossRef

25.

Southey MC, Goldgar DE, Winqvist R, Pylkas K, Couch F, Tischkowitz M, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016;53(12):800–11.PubMedCrossRef

26.

Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750–60.PubMedPubMedCentralCrossRef

27.

Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003;72(4):1023–8.PubMedPubMedCentralCrossRef

28.

Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014;146(5):1208–11 e1 5.PubMedCrossRef

29.

Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomark Prev. 2006;15(2):312–4.CrossRef

30.

Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, et al. Taylor WA Consensus guidelines on genetictesting for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31.PubMedPubMedCentralCrossRef

31.

Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;32(8):824–9.PubMedPubMedCentralCrossRef

32.

Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35(20):2232–9.PubMedPubMedCentralCrossRef

33.

Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ. Jagsi R Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531–4.PubMedPubMedCentralCrossRef

34.

Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800–6.PubMedPubMedCentralCrossRef

35.

Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4:CD002748.PubMed

36.

Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, et al. Evans DG Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat. 2013;142(3):611–8.PubMedCrossRef

37.

Padamsee TJ, Wills CE, Yee LD, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. 2017;19(1):34.PubMedPubMedCentralCrossRef

38.

Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ. Boughey JC Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23(10):3232–8.PubMedPubMedCentralCrossRef

39.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.PubMedCrossRef

40.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Conte P Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.PubMedCrossRef

41.

Mylavarapu S, Das A, Roy M. Role of BRCA mutations in the modulation of response to platinum therapy. Front Oncol. 2018;8(16):16.PubMedPubMedCentralCrossRef

42.

Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.PubMedPubMedCentralCrossRef

43.

Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Frebourg T Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52.PubMedCrossRef

44.

Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, Konig R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):1450–7.PubMedCrossRef

45.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, et al. Narod SA Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107(1):24–30.PubMedPubMedCentralCrossRef

46.

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9.PubMedPubMedCentralCrossRef

47.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.PubMedPubMedCentralCrossRef

48.

Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.PubMedPubMedCentralCrossRef

49.

• Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, et al. Utility of expedited hereditary cancer testing in the surgical management of patients with a new breast cancer diagnosis. Ann Surg Oncol. 2018;25(12):3556–62 An important paper which demonstrates the importance of expanded panels when testing for hereditary breast cancer. PubMedCrossRef

50.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825–35.PubMedPubMedCentralCrossRef

51.

Yadav S, Reeves A, Campian S, Paine A, Zakalik D. Outcomes of retesting BRCA negative patients using multigene panels. Familial Cancer. 2017;16(3):319–28.PubMedCrossRef

52.

• Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, et al. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Breast Cancer Res Treat. 2017;163(2):383–90 An important study which shows the benefits of expanded testing when considering hereditary breast cancer. PubMedPubMedCentralCrossRef

53.

Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, et al. Arun BK Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018;7(6):2718–26.PubMedPubMedCentralCrossRef

Title: Panel Testing for Hereditary Breast Cancer: More or Less?
Authors: Kara K. Landry
Marie E. Wood
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Current Breast Cancer Reports / Issue 2/2020
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-020-00361-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2020

Ductal Carcinoma In Situ—Pathological Considerations

Implications of BRCA Germline Mutations on Breast Cancer Medical Treatment

Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era

Breast Self-Examination: the Case for a Second Look

Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System

Ductal Carcinoma In Situ (DCIS): the Importance of Patient-Reported Outcomes (PRO)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer